Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
Background Primary and secondary progressive multiple sclerosis (MS), collectively called
progressive multiple sclerosis (PMS), is characterized by gradual progression of disability …
progressive multiple sclerosis (PMS), is characterized by gradual progression of disability …
Glial modulators as potential treatments of psychostimulant abuse
PM Beardsley, KF Hauser - Advances in pharmacology, 2014 - Elsevier
Glia (including astrocytes, microglia, and oligodendrocytes), which constitute the majority of
cells in the brain, have many of the same receptors as neurons, secrete neurotransmitters …
cells in the brain, have many of the same receptors as neurons, secrete neurotransmitters …
[HTML][HTML] Targeting distinct tautomerase sites of D-DT and MIF with a single molecule for inhibition of neutrophil lung recruitment
We report a new inflammatory activity for extracellular d-dopachrome tautomerase (D-DT),
the recruitment of neutrophils to the lung on D-DT intratracheal installation of C57BL/6J mice …
the recruitment of neutrophils to the lung on D-DT intratracheal installation of C57BL/6J mice …
Ibudilast attenuates alcohol cue–elicited frontostriatal functional connectivity in alcohol use disorder
Background Ibudilast, a novel neuroimmune modulator being studied to treat alcohol use
disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce …
disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce …
D-dopachrome tautomerase in cardiovascular and inflammatory diseases-A new kid on the block or just another MIF?
C Zan, B Yang, M Brandhofer… - Faseb …, 2022 - epub.ub.uni-muenchen.de
Macrophage migration inhibitory factor (MIF) as well as its more recently described structural
homolog D-dopachrome tautomerase (D-DT), now also termed MIF-2, are atypical cytokines …
homolog D-dopachrome tautomerase (D-DT), now also termed MIF-2, are atypical cytokines …
Advances and insights for small molecule inhibition of macrophage migration inhibitory factor
V Trivedi-Parmar, WL Jorgensen - Journal of medicinal chemistry, 2018 - ACS Publications
Macrophage migration inhibitory factor (MIF) is an upstream regulator of the immune
response whose dysregulation is tied to a broad spectrum of inflammatory and proliferative …
response whose dysregulation is tied to a broad spectrum of inflammatory and proliferative …
Neuroinflammation in amyotrophic lateral sclerosis and frontotemporal dementia and the interest of induced pluripotent stem cells to study immune cells interactions …
E Liu, L Karpf, D Bohl - Frontiers in Molecular Neuroscience, 2021 - frontiersin.org
Inflammation is a shared hallmark between amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD). For long, studies were conducted on tissues of post-mortem …
frontotemporal dementia (FTD). For long, studies were conducted on tissues of post-mortem …
[HTML][HTML] Ibudilast (MN-166) in amyotrophic lateral sclerosis-an open label, safety and pharmacodynamic trial
S Babu, BG Hightower, J Chan, NR Zürcher… - NeuroImage: Clinical, 2021 - Elsevier
Abstract Ibudilast (MN-166) is an inhibitor of macrophage migration inhibitory factor (MIF)
and phosphodiesterases 3, 4, 10 and 11 (Gibson et al., 2006; Cho et al., 2010). Ibudilast …
and phosphodiesterases 3, 4, 10 and 11 (Gibson et al., 2006; Cho et al., 2010). Ibudilast …
Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor–AMP-activated protein kinase signal transduction
J Wang, C Tong, X Yan, E Yeung, S Gandavadi… - Circulation, 2013 - Am Heart Assoc
Background—Macrophage migration inhibitory factor (MIF) exerts a protective effect on
ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules …
ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules …
Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and …
CNS immune signaling contributes to deleterious opioid effects including hyperalgesia,
tolerance, reward, and dependence/withdrawal. Such effects are mediated by opioid …
tolerance, reward, and dependence/withdrawal. Such effects are mediated by opioid …